Kodiak Sciences Inc. (KOD) Form 10-Q — Aug 13, 2026
Kodiak Sciences reported a Q2 2026 net loss of $65.6 million ($1.05 per share) and a first-half loss of $123.8 million, with R&D spending up $13.3 million year over year to $56.1 million as its three Phase 3 programs ramp. The company disclosed substantial doubt about its ability to continue as a going concern, stating its $125.9 million of cash may not cover operating and capital needs for the 12 months after the filing. Operating cash burn accelerated to $86.2 million in H1 2026 from $63.8 million a year earlier, leaving roughly three quarters of runway at the current pace.
Key figures
- Total Assets
- 256811000
- Cash Position
- 125903000
- Shares Outstanding
- 62849457
- Restricted cash
- 6184000
- Ga expense q2 2026
- 10755000
- Rd expense q2 2025
- 42760000
- Rd expense q2 2026
- 56083000
- Accumulated deficit
- 1682506000
- Stockholders equity
- 61096000
- Royalty sale liability
- 100000000
- Public offering costs paid
- 303000
Price after filing
Close on the filing date to close N calendar days later (from $42.11). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.